Vista Pharmaceuticals Limited

VISTAPH6

INE427C01021

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:58 27/06/2024 BST			5-day change	1st Jan Change
12.61 ^INR	-3.00%		-6.87%	-14.04%

05-28	Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
02-10	Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Vista Pharmaceuticals Limited Appoints Chakravarthula Divya Bhavani as Additional Director, Non-Executive, Independent

February 24, 2018 at 07:01 am

Vista Pharmaceuticals Limited announced that at the board of directors meeting held on Feb. 24, 2018, it approved the appointment of Ms. Chakravarthula Divya Bhavani as additional director (non-executive, independent) on the board of the company.

Latest news about Vista Pharmaceuticals Limited

Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-28	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-10	CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding	01-07	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-10	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	12/08/23	CI
Vista Pharmaceuticals Limited Announces the Resignation of Mr. Nishant Talreja from the Post of Company Secretary, Compliance Officer and Key Managerial Personnel	16/06/23	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	30/05/23	CI
Vista Pharmaceuticals Limited Announces Change in Corporate Office Address	10/04/23	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/02/23	CI
Vista Pharmaceuticals Limited announced that it has received INR 61.895 million in funding	13/12/22	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	15/11/22	CI
Vista Pharmaceuticals Appoints Chairman	20/10/22	MT
Vista Pharmaceuticals Limited Announces Executive Changes	14/10/22	CI
Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Independent Director of the Company	08/09/22	CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 66.895 million in funding	02/09/22	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/08/22	CI
Vista Pharmaceuticals Limited Announces Resignation of Akash Bhagadia as Company Secretary and Compliance Officer	27/06/22	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	30/05/22	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/05/22	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	13/11/21	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	14/08/21	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	30/06/21	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	12/02/21	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	12/11/20	CI

Chart Vista Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Vista Pharmaceuticals Limited is an India-based company that is engaged in manufacturing and selling of pharmaceutical, medical, and veterinary preparations. The Company also sells the products to its related companies, which are engaged in the manufacture of formulations. It offers over the counter and prescription generic drug products, consisting of tablets, capsules and liquids covering various therapeutic categories. Its products include tablet dosage forms in the United States market, such as Sulfamethoxazole & Trimethoprim, Acetaminophen, Bismuth Subsalicylate, Bismuth Subgallate, Ferrous Gluconate, Ferrous Sulfate, Pyrantel Pamoate and Isoxsuprine HCl and tablet dosage forms in the non-United States market, such as Aspirin, Atenolol, Mebendazole, Nefidipine, Quinine Sulfate, Ranitidine HCl, Magnesium Trisilicate Compound, Aluminium Hydroxide, Folic Acid and Captopril. Its capsule dosage forms in the non-United States market include Indomethacin, Piroxicam and Nefidipine.

Sector

Pharmaceuticals

Calendar

11/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
VISTA PHARMACEUTICALS LIMITED	-14.04%	10.3M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.39%	43.67B
OTSUKA HOLDINGS CO., LTD.	+26.21%	22.79B
SANDOZ GROUP AG	+21.54%	15.45B
CIPLA LIMITED	+18.82%	14.29B
ZYDUS LIFESCIENCES LIMITED	+53.37%	12.83B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.88%	6.52B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.62%	5.59B